What the FDA labels say about taking them together
Glecaprevir/pibrentasvir and simvastatin
Glecaprevir/pibrentasvir's FDA label of June 25, 2025 names simvastatin in its drug interactions section; the simvastatin label PlainMeds reads does not name glecaprevir/pibrentasvir. The glecaprevir/pibrentasvir label: “Coadministration may increase the concentration of atorvastatin, lovastatin, and simvastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. …”
Check it at the source: the glecaprevir/pibrentasvir FDA label on DailyMed (effective June 25, 2025, AbbVie Inc.); the simvastatin FDA label on DailyMed (effective March 28, 2025, Organon LLC).
What does the glecaprevir/pibrentasvir label say about simvastatin?
Glecaprevir/pibrentasvir label, drug interactionsConcomitant Drug Class/Drug Name: Atorvastatin Lovastatin Simvastatin; Effect on Concentration: ↑ atorvastatin ↑ lovastatin ↑ simvastatin; Clinical Comments: Coadministration may increase the concentration of atorvastatin, lovastatin, and simvastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Coadministration with these statins is not recommended.
Source: FDA drug label (Mavyret), AbbVie Inc., effective June 25, 2025 (SPL set 7bf99777-0401-9095-8645-16c6e907fcc0), via openFDA; the full label on DailyMed
What does the simvastatin label say about glecaprevir/pibrentasvir?
Simvastatin's label (effective March 28, 2025) does not name glecaprevir/pibrentasvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ZOCOR), Organon LLC, effective March 28, 2025 (SPL set 8f55d5de-5a4f-4a39-8c84-c53976dd6af9), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glecaprevir/pibrentasvir | Simvastatin | |
|---|---|---|
| Labeled for | Hepatitis C | Heart attack and coronary artery disease, High cholesterol, High triglycerides |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $152.98 per tablet 100-40 mg tablet | $0.0321 per tablet 20 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once